T’jollyn, Huybrecht
Ackaert, Oliver http://orcid.org/0000-0002-5908-5200
Chien, Caly
Lopez-Gitlitz, Angela
McCarthy, Sharon
Ruixo, Carlos Perez
Karsh, Lawrence
Chi, Kim
Chowdhury, Simon
Ruixo, Juan-Jose Perez
Agarwal, Neeraj
Funding for this research was provided by:
Janssen Research and Development
Article History
Received: 22 December 2021
Accepted: 17 March 2022
First Online: 2 April 2022
Declarations
:
: HT, OA, CC, ALG, SM, JJPR, and CPR: Employees of Janssen Research & Development at time of conduct of the study; CC, ALG, SM, and JJPR: Stock owners of Johnson & Johnson at time of conduct of the study. NA: Consultancy: Astellas, Astra Zeneca, Bayer, Bristol Myers Squibb, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Janssen, Merck, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics; Research funding: Astra Zeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Glaxo Smith Kline, Immunomedics, Janssen, Medivation, Merck, Nektar, New Link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon. KC: Honoraria: Novartis, Janssen, Astellas, Sanofi, Astra Zeneca, Roche, Daiichi Sankyo, Pfizer, and Point Biopharma; and Research funding: Novartis, Janssen, Astellas, Sanofi, Astra Zeneca, and Roche. SC: Consultancy: Clovis Oncology, Astellas Pharma, Bayer, Pfizer, and Janssen-Cilag; Honoraria: Clovis Oncology, and Novartis; Speakers’ Bureau: Pfizer; Research funding: Sanofi/Aventis. LK: Stock Owner: Swan Valley Medical; Honoraria: Astellas, Bayer, Janssen, Pfizer and Dendreon; Consultancy: 3D Biopsy, Astellas, Astra-Zeneca, Bayer, Dendreon, Ferring, Janssen, Pfizer, and Vaxiion; Speakers’ Bureau: Astellas, Bayer, Janssen, Pfizer, and Clovis; Travel, Accommodations, Expenses: Astellas, Bayer, Janssen, Pfizer, and Dendreon; Research funding: Astellas, Astra Zeneca, Bayer, BioXcel Therapeutics, Bristol Meyers Squibb, CU Optics, CUSP, Dendreon, Epizyme, Exact Sciences, Ferring, FKD, Genentech/Roche, GenomeDx, Genomic Health, Janssen, Merck, Myovant, Nucleix, OncoCell MDx, Pfizer, Pharmtech/Veru, Precision Med, QED Therapeutics, Siemens, Urogen, and Vaxiion.
: The study was conducted in accordance with principles for human experimentation as defined in the Declaration of Helsinki and was approved by the Human Investigational Review Board of each study center and by the Competent Authority of each country.
: Informed consent was obtained from each subject before enrollment in the study, after being advised of the potential risks and benefits, as well as the investigational nature of the study.